The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Chiasma disavows any obligation to update the information contained in such press releases after the date of their issuance.
|02/18/13||Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin®|
|For acromegaly and neuroendocrine tumors Basel,
Switzerland, New York, USA, and Jerusalem, Israel - February 18, 2013.
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma)
Inc., a privately held biopharma company, announced today that they have
entered into an agreement to develop and commercialize Chiasma’s
proprietary product Octreolin, initially for acromegaly and subsequently
for neuroendocrine tumors. Octreolin is an investigational oral form of
the peptide oct... |
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.